20 January 2021>: Database AnalysisMaoshu Zhu 1AB* , Jiading Cai 2C* , Yulong Wu 3D , Xinhong Wu 4E , Lianghua Feng 5AF* , Zhijiang Yin 6AG
Med Sci Monit 2021; 27:e928195
Figure 9 Chemosensitivity and immune infiltration differ between gastric cancer RBP subtypes. (A) Box plots depicting the difference in sensitivity to 20 chemotherapy drugs including A.443654 (P=0.999999985), A.770041 (P=0.000181248), ABT.263 (P=1.42×10−9), ABT.888 (P=0.98841534), AG.014699 (P=7.49×10−29), AICAR (P=0.959372747), AKT.inhibitor VIII (P=0.999999804), AMG.706 (P=3.80×10−28), AP.24534 (P=6.32×10−32), AS601245 (P=1.52×10−5), ATRA (P=0.000595412), AUY922 (P=0.000114653), Axitinib (P=3.53×10−11), AZ628 (P=0.999104068), AZD.0530 (P=3.53×10−11), AZD.2281 (P=2.49×10−17), AZD6244 (P=0.995523384), AZD6482 (P=9.92×10−20), AZD7762 (P=9.29×10−17), and AZD8055 (P=4.47×10−27) between the 2 clusters. IC50, the half-maximal inhibitory concentration. (B) Differences in fractions of different immune cells between the 2 subtypes. (C) Differences in expression patterns of different immune-related markers between the 2 subtypes. * P<0.05; ** P<0.01; *** P<0.001; ns – no statistical significance.